FIELD: medicine.
SUBSTANCE: invention relates to treatment of estrogen-positive (ER+) forms of cancer. What is presented is using an elacestrant or a pharmaceutically acceptable salt or solvate thereof for inhibiting and reducing palbociclib-resistant, ribocyclib-resistant or abemacyclib-resistant estrogen receptor-alpha-positive cancer in a subject.
EFFECT: elacestrant has been shown to successfully inhibit growth of cancer cells which are resistant to palbociclib, ribociclib or abemaciclib.
19 cl, 2 ex, 52 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER ON MODELS HAVING ESR1 MUTATIONS | 2019 |
|
RU2822195C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2747228C2 |
| METHODS FOR TREATING CANCER | 2016 |
|
RU2745678C2 |
| METHODS OF TREATING AR+ BREAST CANCER | 2017 |
|
RU2769527C2 |
| COMBINATION THERAPY FOR TREATMENT OF MAMMARY GLAND CANCER | 2018 |
|
RU2764724C2 |
| METHODS OF TREATING CANCER | 2016 |
|
RU2737496C2 |
| METHODS FOR TREATMENT OF OVARIAN CANCER | 2017 |
|
RU2772432C2 |
| COMPLEX THERAPY FOR CANCER TREATMENT | 2018 |
|
RU2810487C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
